Ipca Laboratories Ltd. (NSE: IPCALAB) and Wockhardt Ltd (NSE: WOCKPHARMA) are both listed in the Medicinal Chemicals and Botanical Products industry. Ipca Laboratories has a market capitalisation of ₹49,470 Cr and Wockhardt ₹30,817 Cr, as of 9 Nov 2026. Their P/E ratios are 43.4 and 144.8 respectively. Return on equity is 13.22% for Ipca Laboratories and 4.00% for Wockhardt. Over one year, Ipca Laboratories's share price is up 54.2% and Wockhardt's is up 43.7%.
| Metric | Ipca Laboratories | Wockhardt |
|---|---|---|
| NSE Symbol | IPCALAB | WOCKPHARMA |
| BSE Code | 524494 | 532300 |
| Share Price | ₹1,960.00 | ₹2,031.50 |
| Market Cap | ₹49,470 Cr | ₹30,817 Cr |
| P/E Ratio | 43.4 | 144.8 |
| Return on Equity | 13.22% | 4.00% |
| Return on Assets | 8.42% | 3.67% |
| Dividend Yield | 0.31% | 0.00% |
| Beta (1Y) | -0.04 | 1.03 |
| 1-Year Price Change | +54.2% | +43.7% |
| 3-Month Price Change | +16.3% | +5.2% |
| 52-Week Range | ₹1,293.90 – ₹2,038.00 | ₹1,086.70 – ₹2,422.30 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,910 Cr | ₹969 Cr |
| Quarterly Net Profit | ₹389 Cr | ₹73 Cr |
| Net Margin | 13.4% | 7.5% |
| EPS (Basic, Quarter) | ₹14.79 | ₹4.85 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, …
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafith…
Ipca Laboratories has a market capitalisation of ₹49,470 Cr, against ₹30,817 Cr for Wockhardt as of 9 Nov 2026, about 1.6 times the size by market cap.
Ipca Laboratories has a P/E of 43.4 and Wockhardt a P/E of 144.8 as of 9 Nov 2026.
Ipca Laboratories has a return on equity of 13.22% and Wockhardt 4.00%.
Ipca Laboratories's share price is up 54.2% over one year and Wockhardt's is up 43.7%.
Ipca Laboratories reported revenue of ₹2,910 Cr and net profit of ₹389 Cr for Q2 FY27. Wockhardt reported revenue of ₹969 Cr and net profit of ₹73 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.